Antiplatelet therapy in high-bleeding risk patients with acute coronary syndrome: pharmacogenomics in the era of precision medicine
{{output}}
The management of high-bleeding risk (HBR) patients undergoing percutaneous coronary intervention (PCI) for an acute coronary syndrome (ACS) remains a significant challenge, requiring careful balancing of ischemic prevention and bleeding avoidance. Bleeding ri... ...
